findmyKOL
Clinical trialNCT05239533Active, not recruitingPhase 2Interventional

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment9Advanced Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (limited Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (limited Protocol Activities)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Suffolk-Commack (limited Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (limited Protocol Activites)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center (all Protocol Activities)

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (limited Protocol Activites)

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

177Lu-labeled-girentuximabNivolumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Feb 2022
Primary completion
31 Mar 2027
Completion
31 Mar 2027
Last update posted
14 Jan 2026
Registered enrollment
9
Registry id
NCT05239533
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.